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Abstract 
 
Background 
Obesity is an important risk factor for resistance to insulin-mediated glucose 
disposal, and is a precursor of type 2 diabetes and other disorders.  
 
Objectives 
To identify molecular pathways in adipose tissue and inflammatory cells that may 
result in obesity-associated insulin resistance, we exploited the fact that not all 
obese individuals are prone to insulin resistance.  Thus the degree of obesity as 
a variable was removed by studying obese subjects of similar body mass index 
(BMI) who are insulin-sensitive (IS) versus insulin-resistant (IR).  
 
Methods 
Combining gene expression profiling with computational approaches, we 
determined the global gene expression signatures of omental and subcutaneous 
adipose tissue samples obtained from 10 obese-IR and 10 obese-IS patients 
undergoing gastric bypass surgery.  In a secondary study, we isolated 
monocytes from 4 obese-IR, 3 obese-IS, and 4 nonobese-IS adolescent and 
young adult subjects for purposes of assessing differences in expression of 
inflammatory genes in monocytes using RT-PCR.   
 
 
 vi 
 
Results 
Gene sets related to chemokine activity and chemokine receptor-binding were 
identified as most highly enriched in the omental tissue from obese-IR compared 
to obese-IS subjects, independent of BMI.  Strikingly, insulin resistance, but not 
BMI, was associated with increased macrophage infiltration in the omental 
adipose tissue, as was adipocyte size. 
In the adolescent and young adult cohort, expression of two cytokine signaling 
molecules (IL8, SOCS3) and two downstream products of the JNK pathway 
(JunB, c-Fos) showed increased expression in the obese-IR subjects compared 
to the obese-IS and nonobese-IS subjects, suggesting the presence of a 
proinflammatory phenotype in monocytes in obesity, which is exacerbated in the 
insulin resistant state.      
 
Conclusions 
Our findings demonstrate that inflammation of omental adipose tissue and 
activation of proinflammatory monocytes is strongly associated with insulin 
resistance in human obesity.  Manipulation of these pathways may result in the 
prevention of or delay in the onset of obesity-related co-morbidities. 
 
 vii 
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CHAPTER I 
1. Introduction 
1.1 Description of the research problem 
The prevalence and severity of obesity are increasing dramatically in the United 
States placing millions of Americans at risk for obesity-related co-morbidities 
including type 2 diabetes mellitus (T2DM), and its precursor state of insulin 
resistance (IR).  Interestingly, one-third of obese individuals do not manifest 
obesity-related co-morbidities, highlighting the importance of identifying specific 
genetic and biological factors that place certain obese individuals at the greatest 
risk for obesity-related complications.  Adipose inflammation, systemic cytokines 
and inflammatory cells (such as macrophages) are known to contribute to insulin 
resistance.   In depth exploration of these factors in obese humans with varying 
degrees of insulin resistance may provide further insights into the 
pathophysiology of insulin resistance, detect individuals at the greatest risk for 
developing obesity-related co-morbidities, and identify therapeutic targets to 
prevent these complications.   
 
1.2 Overview of thesis 
Our first objective was to identify genes potentially involved in mediating obesity-
related insulin resistance.  To this end, we determined the gene expression 
profiles of subcutaneous and visceral adipose tissue from obese insulin-resistant 
(obese-IR) and obese insulin-sensitive (obese-IS) adults that had similar body 
 2 
mass index (BMI) levels.  The results from this study identified inflammation and 
adipose tissue macrophage infiltration as histologic findings that are strongly 
associated with insulin resistance.  This information guided our next objective, 
namely to assess the role of monocytes, the macrophage precursors, in insulin 
resistance.  To this end, we isolated monocytes from obese-IR, obese-IS, and 
nonobese-IS adolescents and young adults for purposes of assessing 
differences in expression of inflammatory genes in monocytes.  Results from this 
study may provide clues regarding the pathophysiology of insulin resistance in 
young individuals, suggest biomarkers for identifying at-risk individuals, and 
indicate therapeutic targets for preventing or delaying obesity-related 
complications. 
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CHAPTER II 
2. Related work (Part 1) 
2.1 Obesity and related co-morbidities 
The prevalence and severity of obesity are increasing dramatically in the United 
States and throughout the world1.  The frequency of obesity more than doubled 
in adult Americans and the prevalence of overweight individuals more than tripled 
in U.S. children between 1980 to 20042.  According to data from the National 
Health and Nutrition Examination Surveys (NHANES), 86% of U.S. adults and 
30% of U.S. children will be overweight by 2030 if current trends persist3
 
.  This 
obesity epidemic places millions of Americans at risk for obesity-related co-
morbidities including type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia 
and coronary artery disease.   
2.2 Relationship between insulin resistance, adipose tissue and 
 inflammation 
Obesity induced insulin resistance, a precursor to T2DM, is characterized by a 
decreased response to insulin signaling.  The current mechanisms thought to 
cause insulin resistance are controversial, and involve either ectopic lipid 
deposition in nonadipose tissues4, impairment of insulin signaling by circulating 
cytokines5, or a combination of the two mechanisms.  In both scenarios, adipose 
tissue plays a major role, either by its inability to expand in order to meet energy 
storage demands, or its contribution to the elevation of systemic inflammatory 
 4 
cytokines.  Numerous studies have shown that an increase in circulating 
inflammatory markers in obese subjects, including tumor necrosis factor-α 
(TNFα), interleukin-6 (IL6) and c-reactive protein (CRP), is associated with the 
development of diabetes6,7.  Intensive lifestyle interventions that result in modest 
weight loss can improve the inflammatory state, reduce markers of inflammation, 
and delay or prevent the onset of diabetes as evidenced by multiple studies 
including the Diabetes Prevention Program8-11
    
. 
2.3 Adipose tissue macrophages contribute to insulin resistance 
Cytokines are thought to cause insulin resistance by directly impairing muscle 
insulin signaling and by increasing lipolysis resulting in excess circulating fatty 
acids and enhanced ectopic lipid deposition in insulin responsive organs12.  The 
source(s) of the inflammatory cytokines that are elevated in obesity and obese-IR 
have yet to be determined.  However, several inflammatory cytokines are 
secreted from adipose tissue, which is comprised of multiple cell types including 
adipocytes and macrophages.  Adipose tissue in obese individuals is 
characterized by macrophage infiltration, which is thought to be the predominant 
source of the proinflammatory factors12
 
.  The ability of both adipocytes and 
adipose tissue macrophages to secrete circulating cytokines that contribute to 
insulin resistance highlights the importance of the role adipose tissue plays in 
glucose homeostasis and whole body metabolism. 
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2.4 Gene expression data from adipose tissue provide insights into insulin 
 resistance 
Despite increasing awareness of the role inflamed adipose tissue plays in obesity 
related co-morbidities (i.e. insulin resistance, dyslipidemia, hypertension), there is 
limited understanding of the molecular signals that initiate the inflammatory 
process.  To address this question, most gene expression profiling studies have 
examined differences in adipose tissue gene expression between obese and 
lean subjects and found that obesity is associated with an increase in the 
expression of proinflammatory genes13,14.  To further complicate matters, adipose 
tissue is subdivided into subcutaneous and visceral depots, each of which has 
unique physiologic properties and distinct roles in pathophysiology5.  Expansion 
of the visceral adipose depot correlates with an increased risk of cardiovascular 
disease and diabetes, which may be a function of the close proximity of this 
adipose depot to the liver via the portal circulation5. Increased expression of 
genes associated with immune and defense responses, particularly monocyte 
chemoattractant protein 1 (MCP also known as CCL2) was observed in the 
subcutaneous tissue of obese subjects when compared to lean subjects13.  A 
separate study reported increased expression of proinflammatory and adipogenic 
genes and decreased expression of lipogenic and insulin signaling genes in non-
diabetic obese women compared to lean women14.  However, in both studies, 
limited information was provided regarding the insulin sensitivity of the 
participants, so the obese group may have been heterogeneous with respect to 
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obesity related co-morbidities.  Therefore, these studies cannot reveal genes 
responsible for the metabolically compromised status of some obese individuals 
compared to other obese individuals.  Maclaren, et al showed that changes in 
expression of genes encoding proteins in the insulin signaling pathway were 
greater in omental than in subcutaneous tissue, and were related to insulin 
resistance rather than obesity15
 
.  However, it is difficult to know if this is a cause 
of insulin resistance or merely a response to the increased levels of circulating 
insulin in the insulin resistant population. 
2.5 Obese insulin-sensitive phenotype 
While obesity places many individuals at risk for multiple co-morbidities, one-third 
of obese individuals do not manifest obesity-related comorbidities16,17, 
highlighting the importance of identifying specific genetic and biological factors 
that place certain obese individuals at the greatest risk for obesity-related 
complications.  Insulin-sensitive obese patients typically display an early onset of 
obesity, a fasting insulin level within the normal range, a normal distribution of 
excess fat, normal triglycerides and increased high density lipoprotein (HDL)-
cholesterol when compared to their insulin-resistant obese peers16.   To identify 
genes potentially involved in mediating obesity-related insulin resistance, we 
determined the gene expression profiles of subcutaneous and visceral adipose 
tissue from obese-IR and obese-IS adults who had similar BMI levels and who 
were undergoing gastric bypass surgery.  Our hypothesis is that candidate genes 
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identified by differential expression in this screen would be directly related to 
insulin resistance and not simply a feature of the obese state.   
 
 8 
CHAPTER III 
3. Details of Research (Part 1) 
3.1 Roux-en-Y gastric bypass population 
Adult patients undergoing a laparoscopic Roux-en-Y gastric bypass surgery 
between October 2005 and May 2009 were recruited for this study at the 
University of Massachusetts Memorial Medical Center.  This population of 
patients demonstrates a wide spectrum of insulin resistance as reported in 
previous publications18.  All patients were qualified for gastric bypass surgery 
under published NIH consensus guidelines for the treatment of morbidly obese 
patients19.  Our cohort was restricted to patients with BMI levels between 39 and 
55, so the average BMI of the obese-IR patients was similar to the average BMI 
of the obese-IS patients.  Demographic data including age, gender, height, 
weight, and calculated BMI were measured in the Weight Center.  Fasting 
glucose and insulin levels were recorded at the time of gastric bypass surgery.  A 
lipid profile (triglycerides, total cholesterol, low-density lipoprotein (LDL) 
cholesterol and  HDL cholesterol) was obtained prior to surgery.  Patients with 
diabetes mellitus were excluded from this study because treatment of this 
metabolic disorder has been shown to alter the gene expression profile20.  
Patients were defined as diabetic if they either used oral hypoglycemic 
medications or insulin.  Adipose tissue samples were taken from lower abdominal 
wall (subcutaneous) and greater omentum (visceral).  All subjects provided 
written informed consent before taking part in the study.  The study was 
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approved by the University of Massachusetts Medical School Institutional Review 
Board. 
 
3.2 Technical details 
Insulin sensitivity 
After an overnight fast, pre-operative serum levels of insulin and glucose were 
determined.  A solid phase chemiluminescent immunoassay was used to 
determine serum insulin levels (IMMULITE 2000 Insulin), whereas levels of 
serum glucose were determined by an oxygen rate method employing a 
Beckman Oxygen electrode (SYNCHRON LX Systems).  The homeostatic model 
of assessment (HOMA2-IR) was used to estimate insulin resistance 
(http://www.dtu.ox.ac.uk) by using fasting glucose (mg/dL) and fasting insulin 
levels (mIU/mL).  A cut point of HOMA2-IR ≥ 2.3 was used to characterize 
subjects as being insulin resistant as validated by previous studies in this patient 
population18
 
.    
Microarray Study 
Paired samples of omental and subcutaneous adipose were obtained from 
fasting patients during gastric bypass surgery. Whole adipose tissue was 
dissected to remove fibrotic tissue and obvious vasculature, and frozen in 0.5 
cm3 sections in liquid nitrogen.  Total RNA was isolated from frozen human 
tissues by homogenizing the tissue in TRIzol (Invitrogen, Carlsbad, CA).  RNA 
 10 
quality was assessed using a denaturing agarose gel.  Total RNA was purified 
using the RNeasy Mini-Kit (Qiagen, Valencia, CA).  Ten micrograms of purified 
total RNA was prepared according to Affymetrix protocols.  Prepared cRNA was 
hybridized to Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays.   
 
GeneChip Expression Array Analysis was performed as previously published21 
filtering for p-value <0.05 and fold change ≥ 2. This method was used to rank the 
genes expressed differentially between IS and IR patients in both the 
subcutaneous and visceral adipose depots.  The gene lists that were obtained 
using the filtering parameters mentioned above were entered into the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics 
database (http://david.abcc.ncifcrf.gov/home.jsp)22,23
 
 to determine which 
molecular functions were most represented in the top-scoring genes using 
information obtained from the Gene Ontology Consortium 
(http://www.geneontology.org).  The data discussed in this publication have been 
deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible 
through GEO Series accession number GSE20950. 
Real-time PCR 
 
RNA isolated from the visceral adipose tissue from the twenty patients was 
analyzed to confirm the microarray analysis findings.  cDNA was synthesized 
using iScript cDNA Synthesis Kit (BioRad, Hercules, CA).  Quantitative real-time 
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PCR for specific genes was performed using SybrGreen normalized to beta 2 
microglobulin.  Primers were designed using PrimerBank which is a public 
resource for PCR primers using a primer design algorithm that has been tested 
by real-time PCR experiments for PCR specificity and efficiency 
(pga.mgh.harvard.edu/primerbank)24.  Melting curve data was collected to 
visualize the presence of primer dimers.  We used the following primers for RT-
PCR: CCL2-sense, 5’-CCC CAG TCA CCT GCT GTT AT-3’; CCL2-antisense, 5’-
TGG AAT CCT GAA CCC ACT TC-3’; IL8-sense, 5’-ACT GAG AGT GAT TGA 
GAG TGG AC-3’; IL8-antisense, 5’-AAC CCT CTG CAC CCA GTT TTC-3’; 
CCL3-sense, 5’-AGT TCT CTG CAT CAC TTG CTG-3’; CCL3-antisense, 5’-
CGG CTT CGC TTG GTT AGG AA-3’; CCL4-sense, 5’-CTG TGC TGA TCC 
CAG TGA ATC-3’; CCL4-antisense, 5’TCA GTT CAG TTC CAG GTC ATA CA-
3’; CCL18-sense, 5’-GGG GGC TGG TTT CAG AAT A-3’, CCL18-antisense, 5’-
CTC CTT GTC CTC GTC TGC AC-3’; Beta2M-sense, 5’-GGC TAT CCA GCG 
TAC TCC AAA-3’; Beta2M-antisense, 5’-CGG CAG GCA TAC TCA TCT TTT T-
3’.  Expression of specific mRNAs was quantified in duplicate samples on an 
iCycler IQ Real-Time PCR detection system (Bio-Rad Laboratories) using the 
∆∆CT
 
 method.  
Adipose tissue histology 
 
Tissues were fixed in 10% buffered formalin and embedded in paraffin from 
which multiple 5-mm sections were obtained.  Images were acquired using an 
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Axioskop2 Plus (Zeiss, Göttingen, Germany) coupled to a Spot RTKe (Diagnostic 
Instruments, Inc) and were analyzed using SPOT 4.0.2 software.  For each 
subject, adipocyte cell diameter was calculated from the perimeter measurement 
(Adobe Photoshop CS4 Extended) and averaged using 100 cells.  
Immunohistochemical detection of CD68 (Santa Cruz Biotechnologies, 
Heidelberg, Germany) diluted 1:50 was performed with the avidin-biotin 
peroxidase method.  Adipocytes and CD68+ cells were counted at 10x 
magnification in ten different randomly chosen areas for omental adipose tissue, 
and five randomly chosen areas for subcutaneous adipose tissue (due to the 
limited size of this tissue sample).   
 
Statistical analysis 
 
Baseline differences between insulin sensitive and insulin resistant subjects were 
evaluated using the Student’s t test for continuous variables and Fisher’s exact 
test for categorical variables.  Variables with a skewed distribution (total 
cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, fasting glucose, 
fasting insulin, HOMA2) were log-transformed before analysis.  For genes 
analyzed by real time-PCR (RT-PCR), significant differences between insulin 
sensitive and insulin resistant groups were determined by Student’s t test.  The 
results were considered significant at P ≤ 0.05.  For Gene Ontology Molecular 
Function gene sets analyzed by DAVID, significant differences between insulin 
sensitive and insulin resistant groups were determined using the Bonferroni 
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correction to address the problem of multiple comparisons.  The results were 
considered significant at Bonferroni P ≤ 0.05.  The relationships between subject 
clinical data (HOMA2-IR or BMI) and characteristics of adipose histology 
(macrophage infiltration or adipocyte diameter) were determined by regression 
analysis.   
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CHAPTER IV 
4. Experimental Evaluation (Part 1) 
4.1 Clinical and metabolic characteristics of the study population 
Adipose tissue samples from 20 subjects were used in this study.  Fourteen of 
the twenty subjects were female and the average age of the study sample was 
42 years (Table 4.1).  Using HOMA2-IR analysis, we divided the subjects into 
two groups: insulin sensitive (n=10) and insulin resistant (n=10).  Insulin resistant 
subjects showed significantly elevated HOMA2-IR as compared to insulin 
sensitive subjects (see Methods).  In addition, both fasting insulin (p < 0.001) and 
fasting glucose (p = 0.02) levels were higher in insulin resistant subjects.  The 
obese-IR group has elevated triglyceride levels compared with the obese-IS 
group, which is not unexpected.  While the 2 groups had similar total cholesterol 
and LDL cholesterol levels, two of the obese-IR patients with low total cholesterol 
and LDL cholesterol levels were on lipid lowering medications which are known 
to lower LDL values (Figure 4.1).  This may account for the similarity in 
cholesterol levels between the two groups. 
 
4.2 Global gene expression profiling of adipose tissue identifies active 
chemokine signaling in obese-insulin resistant patients 
In order to identify genes related to insulin resistance rather than obesity per se, 
we first utilized cDNA microarrays to determine the gene expression profiles of 
paired subcutaneous and omental samples from the 20 obese subjects (one 
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insulin resistant subject did not have a subcutaneous sample available for 
microarray analysis).  Using GeneChip Expression Array Analysis and filtering 
parameters p-value < 0.05 and fold change ≥ 2, we identified 37 genes 
differentially expressed in omental tissue of insulin resistant subjects as 
compared to insulin sensitive subjects, and three genes differentially expressed 
in subcutaneous tissue between the two subject groups (Table 4.2, Figure 4.2). 
 
To elucidate the molecular functions differentially regulated in the omental 
adipose tissue of our subjects, we entered the gene list into the DAVID 
bioinformatics database and identified 2 Gene Ontology Molecular Function gene 
sets as being differentially expressed between the insulin resistant and insulin 
sensitive subjects (Table 4.3).  The gene sets representing chemokine activity 
and chemokine receptor binding were upregulated in omental tissue of insulin 
resistant subjects and reached statistical significance using the Bonferroni 
correction to address the problem of multiple comparisons.  Both gene sets 
included the genes chemokine (C-C motif) ligand 18 (CCL18), chemokine (C-C 
motif) ligand 2 (CCL2), chemokine (C-C motif) ligand 3 (CCL3), chemokine (C-C 
motif) ligand 4 (CCL4) and interleukin 8 (IL8).  These five genes were studied 
with quantitative RT-PCR analysis which revealed that the direction and 
magnitude of the differential expression in omental tissue was consistent with the 
data provided by microarray analysis, thereby confirming the computational 
approach (Fig 4.3).   These trends were upheld when the data were re-analyzed 
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using just the female patients, confirming that the observed differences were not 
due to gender bias (Figure 4.4).    While the expression of these five genes, as 
assessed by signal intensity on the Affymetrix gene chip, was much higher in the 
subcutaneous tissue, there was no difference in expression between the obese-
IR and obese-IS groups (Table 4.4). 
 
 
4.3 Adipose tissue macrophage infiltration and adipocyte size  
To determine whether the differences in chemokine expression with insulin 
resistance were related to changes in adipose tissue composition, we performed 
an immunohistochemical analysis of omental adipose tissue samples from 
eleven patients which comprised a subset of the original cohort of twenty 
patients.  We observed strikingly larger adipocyte size and increased 
macrophage infiltration associated with insulin resistance. (Figures 4.5 4.6)   
There was a significant correlation between HOMA2-IR and macrophage 
infiltration (Fig 4.7) on the other hand, analysis of CD68 staining with BMI in the 
morbidly obese range showed no association (Fig 4.9)  Adipocyte diameter was 
inversely correlated with HOMA2-IR (Figure 4.8) but not with BMI (Figure 4.10) in 
our obese subjects.   
 
Immunohistochemical analysis was performed on the subcutaneous tissue of 
seven patients for comparison (the subcutaneous tissue from the other four 
 17 
patients was poor quality).  On average, the adipocytes were smaller than those 
observed in the omental tissue, there were fewer macrophages, and there was 
not correlation between HOMA2-IR and adipocyte size or macrophage infiltration 
(Figs 4.11 – 4.14).   
 
4.4 Conclusions 
In this study we aimed to identify molecular pathways in adipose tissue related 
directly to insulin resistance in obese adult men and women.  By combining 
expression profiling with computational approaches, we found that elevated 
chemokine and chemokine receptor activity distinguishes the omental adipose 
tissue of insulin resistant obese patients from omental adipose of insulin sensitive 
obese individuals.  In addition, our histological analysis determined that 
increased adipocyte size and increased macrophage infiltration of the adipose 
tissue is associated with insulin resistance and not simply BMI in morbidly obese 
human subjects.   
 
Both human and animal studies demonstrate that hypertrophied adipocytes 
secrete CCL2, which is a chemoattractant that increases macrophage 
infiltration
Multiple chemokines play a role in macrophage recruitment to adipose tissue 
25,26,27.  As such, CCL2 is thought to be the primary chemokine 
secreted from adipose tissue in the obese state, and responsible for adipose 
inflammation leading to subsequent metabolic alterations13.  However, CCL2-
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deficient mice do not have diminished macrophage infiltration or improved 
glucose metabolism compared to control mice28, suggesting that other 
chemokines may play critical a role in the adipose inflammation associated with 
obesity.  The increased expression of five chemokines in the visceral adipose 
tissue of our insulin resistant cohort supports this theory, which has been 
previously demonstrated in studies of obese subjects with lean controls29.  Of 
note, CCL2 did not have the highest fold change of the chemokines we identified 
as being upregulated in insulin resistance.   Interleukin 8/CXCL8, another 
chemokine identified in our insulin resistant sample, is differentially secreted by 
visceral adipose tissue and implicated in coronary heart disease30
 
 suggesting 
importance in obesity related sequelae.  
 
Enlarged adipocyte size is associated with insulin resistance
Adipocyte hypertrophy is associated with insulin resistance 
31, increased 
adipokine production and secretion32,33. In our study population, insulin 
resistance was associated with an increase in adipocyte size.  Chemokines, 
secreted by hypertrophied adipocytes, attract macrophages that can be seen 
dispersed throughout the tissue, or clustered around adipocytes in “crown like 
structures” and secrete cytokines that contribute to the low-grade inflammation 
seen in obesity.  Omental fat appears to have more macrophage infiltration than 
subcutaneous fat, a finding that is exaggerated by central obesity34.  Our data 
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support the hypothesis that the relationship between insulin resistance, adipocyte 
size and macrophage infiltration is not a function of overall weight, but perhaps 
related to one or more unknown factors including adipose distribution or visceral 
adiposity. 
 
The strengths of our study consist of the inclusion of obese subjects with a range 
of insulin sensitivity and the use of microarray data, which allows for the 
unbiased analysis of the expression of multiple genes in different pathways.  By 
restricting the BMI of the obese-IS and obese-IR groups we reduced the 
influence of obesity itself as a variable in examining the association between 
insulin resistance with altered gene expression.  Yet, we recruited a morbidly 
obese population which may raise potential concerns with generalizability of 
findings to a population with a moderate or mild degree of obesity.  One may 
argue that the measurement of BMI may not accurately reflect the degree of 
body fat content and may be strengthened by more objective data on body fat 
composition or waist circumference.  However, recent evidence
Study strengths and limitations 
35 suggests that 
even waist circumference is not a useful measurement in persons with severe 
obesity (BMI ≥ 40).  Thus this issue remains open for further analysis in future 
studies.  Due to our limited group of surgical patients we included both female 
and male subjects in both the insulin resistant and insulin sensitive cohorts. Yet, 
the enrichment of genes encoding chemokines in the omental adipose tissue of 
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insulin resistant patients was observed even when we limited our analysis to the 
female patients (Figure 4.3), making it unlikely that our observed differences 
were due to gender bias.   
 
Our data are consistent with a growing body of evidence suggesting that adipose 
inflammation plays a role in mediating the insulin resistance itself, as it is 
manifest in obesity.  We showed that omental adipose chemokine expression 
and macrophage infiltration is associated with insulin resistance, independent of 
obesity in a morbidly obese population. This study raises the important question: 
why do some obese patients display such inflammation in their omental adipose 
tissue, while other equally obese patients do not?  Pharmaceutical agents aimed 
at interrupting the chemokine pathway may be able to diminish the metabolic 
sequelae associated with obesity.   
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Tables
 
Insulin Sensitive Insulin Resistant 
HOMA < 2.3 HOMA >= 2.3 
(N= 10) (N= 10) P Value 
    0.2 
Mean 39 ± 6 44 ± 9 
Range 31-54 33-57 
8 (80) 6 (60) 0.4 
    0.7 
Mean 48 ± 3 49 ± 7 
Range 46-55 39-60 
Total cholesterol (mg/dL)** 0.9 
Mean 176 ± 27 179 ± 50 
Range 115-211 111-276 
LDL cholesterol (mg/dL)** 0.4 
Mean 109 ± 15 101 ± 45 
Range 76-127 45-190 
HDL cholesterol (mg/dL)** 
Mean 44 ± 5 42 ± 9 0.4 
Range 38-52 30-56 
Triglycerides (mg/dL)** 0.4 
Mean 129 ± 33 166 ± 74 
Range 94-188 74-274 
Lipid lowering therapy - no. (%) 1 (10) 3 (30) 0.3 
    0.02 
Mean 88 ± 9 101 ± 12 
Range 75-100 82-127 
    <0.001 
Mean 9 ± 4 24 ± 7 
Range 4-14 16-36 
    <0.001 
Mean 1.3 ± 0.5 3.6 ± 1 
Range 0.6-2.1 2.4-5.3  
** Data was not available for three patients (1 IS, 2 IR) 
§ The body-mass-index (BMI) is the weight in kilograms divided by the square of 
the height  in meters. 
BMI§ 
Fasting glucose (mg/dL) 
Fasting insulin (mIU/mL) 
HOMA2 
* Plus-minus values are mean ± SD. 
Table 4.1. Clinical and Biochemical Characteristics of the Study Participants* 
Age - yr 
Female sex - no. (%) 
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Probe ID Gene name Symbol FC P  value
OMENTAL DEPOT
203936_s_at matrix metallopeptidase 9 MMP9 2.9 0.001
206932_at cholesterol 25-hydroxylase CH25H 2.8 0.014
216598_s_at chemokine (C-C motif) ligand 2 CCL2 2.7 0.013
202859_x_at interleukin 8 IL8 2.7 0.023
209395_at chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 2.7 0.007
205114_s_at chemokine (C-C motif) ligand 3 CCL3 2.6 0.029
212657_s_at interleukin 1 receptor antagonist IL1RN 2.4 0.005
209875_s_at secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) SPP1 2.2 0.044
230040_at ADAM metallopeptidase with thrombospondin type 1 motif, 18 ADAMTS18 2.2 0.044
205681_at BCL2-related protein A1 BCL2A1 2.1 0.004
213975_s_at lysozyme (renal amyloidosis) LYZ 2.1 0.016
202499_s_at solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3 2.1 0.021
209959_at nuclear receptor subfamily 4, group A, member 3 NR4A3 2.1 0.024
204103_at chemokine (C-C motif) ligand 4 CCL4 2.0 0.044
224009_x_at dehydrogenase/reductase (SDR family) member 9 DHRS9 2.0 0.005
32128_at chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) CCL18 2.0 0.043
229160_at melanoma associated antigen (mutated) 1-like 1 MUM1L1 -2.0 0.019
242662_at Proprotein convertase subtilisin/kexin type 6 PCSK6 -2.0 0.044
232164_s_at epiplakin 1 EPPK1 -2.0 0.024
204364_s_at receptor accessory protein 1 REEP1 -2.0 0.042
229796_at SIX homeobox 4 SIX4 -2.0 0.002
230867_at collagen type VI alpha 6 COL6A6 -2.0 0.015
1555230_a_at Kv channel interacting protein 2 KCNIP2 -2.0 0.015
219895_at family with sequence similarity 70, member A FAM70A -2.0 0.034
224480_s_at 1-acylglycerol-3-phosphate O-acyltransferase 9 AGPAT9 -2.1 0.000
205769_at solute carrier family 27 (fatty acid transporter), member 2 SLC27A2 -2.1 0.013
205960_at pyruvate dehydrogenase kinase, isozyme 4 PDK4 -2.2 0.025
205433_at butyrylcholinesterase BCHE -2.2 0.046
234103_at Potassium channel, subfamily T, member 2 KCNT2 -2.2 0.006
204469_at protein tyrosine phosphatase, receptor-type, Z polypeptide 1 PTPRZ1 -2.3 0.001
206423_at angiopoietin-like 7 ANGPTL7 -2.3 0.003
209309_at alpha-2-glycoprotein 1, zinc-binding AZGP1 -2.3 0.000
214584_x_at acetyl-Coenzyme A carboxylase beta ACACB -2.4 0.001
233314_at phosphatase and tensin homolog (mutated in multiple advanced cancers 1) PTEN -2.4 0.019
209470_s_at glycoprotein M6A GPM6A -2.4 0.002
222853_at fibronectin leucine rich transmembrane protein 3 FLRT3 -2.5 0.019
204560 at FK506 binding protein 5 FKBP5 -2.8 0.010
SUBCUTANEOUS DEPOT
214587_at collagen, type VIII, alpha 1 COL8A1 -2.0 0.031
230867 at collagen type VI alpha 6 COL6A6 -2.1 0.024
1554062 at Xg blood group XG -2.2 0.045
Table 4.2.  Individual genes differentially expressed in adipose tissue from insulin 
resistant compared to insulin sensitive obese patients. 
* Analysis was performed from Affymetrix GeneChip data using Microarray Computational Enviroment 2.0 developed by the Diabetes and 
Endocrinology Research Center at the University of Massachusetts Medical School.  Shown are all named genes significantly upupregulated 2 fold or 
more.  Fold change indicates the difference in expression in insulin resistant as compared to insulin sensitive obese subjects.  The P values were not 
adjusted for multiple testing.  P < 0.05 was considered statistically significant.  Genes with an Absent call were excluded.
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Table 4.4.  Affymetrix gene chip signal intensities for five inflammatory 
genes from omental and subcutaneous tissues. 
  Omental Subcutaneous 
Symbol IR signal IS signal P FC IR signal IS signal P FC 
CCL2 579 214 2.7 0.013 1497 1128 1.3 NS 
IL8 38 14 2.7 0.023 227 247 1.1 NS 
CCL3 161 63 2.6 0.029 198 252 1.3 NS 
CCL4 276 140 2 0.044 329 373 1.1 NS 
CCL18 387 196 2.0 0.043 470 548 1.2 NS 
 
 
 
 24 
Figure Legend 
 
Figure 4.1  Serum levels of total cholesterol, low density lipoprotein (LDL), high 
density lipoprotein (HDL) and triglycerides in obese-IR (red dots) and obese-IS 
(blue squares) subjects.  Subjects receiving pharmacologic treatment with a lipid 
lowering agents are represented by a dark center within their symbol 
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Figure 
 
 
4.1 
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Figure Legend 
 
Figure 4.2. Expression of inflammation-related genes in omental adipose tissue 
from insulin resistant and insulin sensitive obese human subjects using 
microarray data.  Heatmap representing normalized expression of genes 
identified by Microarray Computational Environment (MACE) as being 
significantly increased in omental adipose tissue from insulin resistant subjects 
and insulin sensitive human subjects. The genes are listed on the right.  
Expression levels above the mean for the gene are shown in red and expression 
levels below the mean for the gene are shown in green.   
 
Figure 4.3.  Expression of inflammation-related genes in omental adipose tissue 
from insulin resistant and insulin sensitive obese human subjects using RT-PCR 
data.  Fold change in mRNA level of genes in omental adipose tissue of obese, 
insulin-resistant subjects (n=10) relative to obese, insulin-sensitive subjects 
(n=10) based on microarray data (white bars) and quantitative real-time analysis 
(black bars) performed by RT-PCR. ** P < 0.01; * P < 0.05. 
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Figure Legend 
 
Figure 4.4. Expression of inflammation-related genes in omental adipose tissue 
from insulin resistant and insulin sensitive female obese human subjects using 
microarray and RTqPCR. Fold change in mRNA level of genes in omental 
adipose tissue of female obese, insulin-resistant subjects (n=6) relative to female 
obese, insulin-sensitive subjects (n=8) based on microarray data (white bars) and 
quantitative real-time analysis (black bars) performed by RTqPCR. * P < 0.05. 
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Figure Legend 
 
Relationship between macrophage infiltration, adipocyte diameter and HOMA2-
IR in omental adipose tissue. Immunohistochemical detection of CD68+ 
macrophages performed on omental adipose tissue samples obtained from 
obese human subjects undergoing gastric bypass surgery.  
 
Figure 4.5. CD68 staining of omental adipose tissue from a representative insulin 
sensitive subject.   
 
Figure 4.6. CD68 staining of omental adipose tissue from a representative insulin 
resistant subject.  Unlike in adipose tissue from insulin sensitive subject (4.4) 
macrophages are observed throughout the tissue (arrows) and arranged in 
crown-like structures (arrowhead) in the insulin resistant subject (4.5). Sections 
taken at 20x magnification.   
 
Quantitative analysis of adipocyte diameter and macrophage infiltration in 
adipose tissue of insulin resistant and insulin sensitive obese human subjects.  
 
Figure 4.7. Insulin sensitivity, as determined by HOMA2-IR, correlates with 
CD68+ macrophage infiltration. Data is an average of 10 histological fields using 
10X objective. 
 
Figure 4.8. Insulin sensitivity, as determined by HOMA2-IR, correlates with 
adipocyte diameter. Adipocyte diameter was calculated from the perimeter 
measurement of 100 cells.  
 
 
Figure 4.9. Body mass index (BMI) shows no correlation with macrophage 
infiltration.  Data is an average of 10 histological fields using 10X objective. 
 
Figure 4.10. Body mass index (BMI) shows no correlation with adipocyte 
diameter. Adipocyte diameter was calculated from the perimeter measurement of 
100 cells.  
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Figure Legend 
 
Relationship between macrophage infiltration, adipocyte diameter and HOMA2-
IR in subcutaneous adipose tissue. Immunohistochemical detection of CD68+ 
macrophages performed on subcutaneous adipose tissue samples obtained from 
obese human subjects undergoing gastric bypass surgery.  
 
Figure 4.11. Insulin sensitivity, as determined by HOMA2-IR, does not correlate 
with CD68+ macrophage infiltration. Data is an average of 5 histological fields 
using 10X objective. 
 
Figure 4.12. Insulin sensitivity, as determined by HOMA2-IR, does not correlate 
with adipocyte diameter. Adipocyte diameter was calculated from the perimeter 
measurement of 100 cells.  
 
 
Figure 4.13. Body mass index (BMI) shows no correlation with macrophage 
infiltration.  Data is an average of 5 histological fields using 10X objective. 
 
Figure 4.14. Body mass index (BMI) shows no correlation with adipocyte 
diameter. Adipocyte diameter was calculated from the perimeter measurement of 
100 cells.  
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CHAPTER V 
5. Related work (Part 2) 
5.1 The monocyte/macrophage cell lineage 
While the role of the adipose tissue macrophage in the regulation of insulin 
sensitivity in obese diabetic adults has been described5, less is known about the 
molecular response of the peripheral blood monocyte (macrophage precursor) in 
obesity-induced IR.  Monocytes comprise 10% of the leukocytes in human blood, 
and play an active role in the cellular innate immune system and the 
inflammatory response36.  Chronic activation of innate immunity can lead to the 
undesired development of inflammatory diseases, most notably atherosclerosis.  
In the setting of obesity associated IR, monocytes can serve as a source of 
myeloid precursors for the renewal of adipose tissue macrophages36.  The 
receptors located on the surface of the monocytes detect a variety of stimuli, 
including lipids, which increase in response to a high fat diet36
 
.  Monocytes are 
easily sampled, and may provide insight that can be used to prevent or delay the 
inflammation associated with obesity and insulin resistance. 
5.2 Monocyte subtypes 
Monocytes, as a class, are heterogeneous and differential expression of cell 
surface markers and chemokine receptors distinguish the 2 major subsets.  
Proinflammatory CD14+CD16+ monocytes are more involved in the inflammatory 
response than their classical CD14+CD16- counterparts37.  The CD14+CD16- 
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monocytes comprise 80-90% of monocytes and produce the anti-inflammatory 
cytokine IL10 in response to lipopolysaccharide (LPS) stimulation and free fatty 
acids.  In contrast, proinflammatory CD14+CD16+ monocytes produce TNFα and 
IL-1 in response to LPS stimulation36.  The expression of specific chemokine 
receptors, particularly chemokine (C-C motif) receptor 2 (CCR2) and chemokine 
(C-X3-C motif) receptor 1 (CX3CR1), also distinguishes the two monocyte 
subsets36.  Genetic manipulation of these chemokine receptors in rodent models 
has shown their importance in glucose metabolism.  CCR2 knockout mice have 
reduced macrophage infiltration into adipose tissue and demonstrate an 
improvement in glucose homeostasis and insulin sensitivity38
 
.   
5.3 Monocyte activation 
Circulating monocytes are easily accessible and their molecular profiles may 
provide biological and clinical insights into mechanisms of disease.  There is a 
growing literature on gene expression profiling of monocytes in patients with 
Type 1 diabetes and T2DM.  Monocytes from patients with Type 1 diabetes 
demonstrate increased toll-like receptor expression, upregulation of (NF-κB), and 
elevated secretion of TNF-α, IL6 and IL-1β39,40 as compared to non-diabetic 
subjects.  Monocytes from both Type 1 and Type 2 diabetic patients display 
increased expression of the monocyte chemoattractant protein-1 (MCP-1) gene 
when compared to non-diabetic controls41.  Monocytes from subjects with Type 2 
diabetes exhibit increased proatherogenic activity compared with those from 
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matched control subjects42,43.  Even monocytes from obese metabolically normal 
individuals are shown to be in an inflammatory activated state when compared to 
lean individuals44
 
. 
5.4 Inflammatory pathways 
The inflammatory cytokines that are elevated in obesity and obese-IR as well as 
lipotoxic stress from circulating long-chain saturated free fatty acids and lipids 
activate at least two transcription factor-signaling pathways in adipocytes, 
hepatocytes and macrophages: the NF-κB pathway which is activated upon 
degradation of the inhibitor of NF-κB (IκB) kinase β (IKKβ), and the c-Jun NH2-
terminal kinase (JNK) pathway5,45
 
 (Fig 5.1).  Activation of the NF-κB and JNK 
pathways results in increased expression of NF-κB and AP-1 target gene 
products including IL6, TNFα, IL1β, MCP-1, and IL8, some of which act as 
mediators of IR.  JNK also exerts its effects through inhibition of tyrosine 
phosphorylation of insulin receptor substrate-1 which has a negative effect on 
downstream insulin signaling.   
Genetic disruption of these signaling pathways in rodent models has been shown 
to improve obese-IR in the setting of a high fat diet (HFD), highlighting their 
importance in this disease process.  JNK1 knockout mice are protected against 
diet-induced or genetically induced IR46.  Recently, it was shown that JNK1 
ablation in adipose tissue decreased IL6 production which subsequently  lowered 
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expression of SOCS3, a protein known to mediate hepatic insulin resistance47.  
Additional studies have shown that JNK and NFκB activation in hematopoietically 
derived cells plays a major role in HFD-induced inflammation and IR with little 
impact on obesity.  Targeted JNK1 deletion in the hematopoietic compartment 
protects against HFD-mediated IR by altering obesity-induced inflammation45,  
and cell-specific deletion of IKKβ in myeloid cells protects mice from diet-induced 
IR48.  A two-week trial of salsalate, a modified form of salicylate which inhibits the 
IKKβ/NF-κB axis, was recently shown to improve insulin sensitivity and decrease 
biomarkers of inflammation in a cohort of obese diabetic patients49
 
.  This 
supports the possibility of targeting NF-κB as a therapeutic approach in T2DM. 
5.5 Childhood obesity 
Currently, there are no published studies that have examined the molecular 
response of monocytes in young obese-IR individuals.  One in six overweight 
adolescents has IR50, placing this vulnerable population at increased risk for 
diabetes and heart disease, which are two of the leading causes of morbidity and 
mortality in the U.S.  All children experience a period of physiologic insulin 
resistance during puberty due to changes in body composition and hormone 
levels51, which for some may trigger the onset of pathologic insulin resistance 
that could progress to type 2 diabetes mellitus.  In addition, these adolescents 
are free from other inflammation-related co-morbidities (arthritis, chronic 
obstructive pulmonary disease) and are not taking lipid lowering medications, 
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making them an ideal group to study.  To the extent possible, matching on BMI 
minimizes the impact of obesity as a potential confounding variable.  Targeting 
behavioral modifications and pharmaceutical interventions to treat young 
adolescents at highest risk will hopefully prevent or delay the development of 
diabetes and its complications, which will have dramatic implications for the 
affected individuals as well as their families and society. 
 
To assess the role of monocytes in insulin resistance we conducted a pilot 
investigation and utilized monocytes isolated from obese-IR, obese-IS, and 
nonobese-IS subjects for the purposes of assessing differences in expression of 
inflammatory genes in monocytes using RT-PCR.   
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Figure Legend 
Figure 5.1 Possible stimuli for activating IKKb/NF-kB and JNK pathways in the 
obese state.  Lipids, free fatty acids and cytokines can activate inflammatory 
pathways by binding to TNF-α, IL-1, or Toll receptors (TNFR, IL1R, or TLR).  
Degradation of the inhibitor of NF-κB (IκB) kinase β (IKKβ) allows NF-κB to the 
nucleus leading to increased expression of target genes that are potentially 
involved in the pathogenesis of IR.  JNK also exerts its effects through inhibition 
of tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1).  Adapted from 
“Inflammation and insulin resistance,” by Shoelson S, et al, 2006, The Journal of 
Clinical Investigation, 116, p. 1794. Copyright 2006 by the American Society for 
Clinical Investigation. 
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5.1 
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CHAPTER VI 
6. Details of Research (Part 2) 
6.1 Recruitment of adolescent and young adult subjects 
Female adolescents and young adults between the ages of 16-25 years were 
recruited from the Pediatric Endocrine, Adolescent Medicine, and Nutrition clinics 
at the University of Massachusetts Medical Center in the fall of 2009.  The 
subjects were interviewed by a trained interviewer and underwent a brief physical 
examination (Table 6.1).  Persons with diabetes mellitus, any acute or chronic 
inflammatory disease as determined by clinical signs of infection, clinical 
evidence of either cardiovascular or peripheral artery disease, thyroid disease, 
Cushing´s disease or hypercortisolism, pregnancy, and those receiving 
medications that may affect our outcome parameters (metformin, lipid lowering 
medication, antihyperglycemic agents, steroids, non-steroidal anti-inflammatory 
drugs three days prior to blood draw) were excluded.  Obese was defined as BMI 
> 95% for age.  Nonobese was defined as BMI > 5% and < 75% for age. 
 
A 40 mL sample of whole blood was obtained via venipuncture in the fasting 
state, and evaluated for metabolic and inflammatory parameters (Table 6.1).  
Insulin resistance was defined as homeostasis model of insulin resistance 
(HOMA-IR) ≥ 3.16. HOMA-IR is a surrogate measure of IR derived using the 
following formula: [Glucose (mg/dL) * Insulin (mIU)]/405.  Several tools are 
available for defining IR, the gold standard being the hyperinsulinemic-
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euglycemic clamp technique52.  However, this method is invasive, complicated 
and time-consuming.  The HOMA-IR is a more practical method to measure IR, 
and has been used in a large epidemiologic study in an adolescent population53.  
The cutoff of 3.16 was validated in a population of obese children and 
adolescents with IR as determined by an oral glucose tolerance test54
 
.  The study 
was approved by the University of Massachusetts Medical School Institutional 
Review Board. 
6.2 Technical details 
Blood sample collection and monocyte isolation: Blood samples were obtained 
via venipuncture after an overnight fast.  Venous blood (40 mL total) was 
collected in six VacutainerTM Cell Preparation Tubes (Becton Dickinson, 
Rutherford, NJ) with Na Citrate which are intended for the collection of whole 
blood and the separation of mononuclear cells using a FICOLLTM HypaqueTM 
solution. An additional 5 mL were collected in an EDTA tube (VacutainerTM, 
Becton Dickinson) for whole blood hematology analysis.  Blood mononuclear 
cells were isolated from the VacutainerTM
 
 Cell Preparation Tubes via 
centrifugation.  Untouched primary monocytes were further isolated from the 
mononuclear fraction using a negative selection kit (Miltenyi Biotec, Germany). 
RNA isolation: RNA was isolated from monocytes according to the QIAGEN 
MiniPrep protocol.  cDNA from total RNA was synthesized using the iScript cDNA 
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Synthesis Kit (Bio-Rad Laboratories).  Real-time PCR to quantify expression of 
inflammatory cytokines was performed using SybrGreen assays according to the 
manufacturer’s instructions (Bio-Rad Laboratories).  Expression of specific 
mRNAs was quantified in duplicate samples on an iCycler IQ Real-Time PCR 
detection system (Bio-Rad Laboratories) using the ∆∆CT method with 
normalization to cycle threshold measurements for beta 2 microglobulin.  
 
Serum cytokine quantification
 
: Serum levels of leptin and inflammatory cytokines 
of interest (IL6, IL8, TNFα) were measured in fasting blood samples using the 
Milliplex™ immunoassay kit. 
Statistical analysis:  Baseline differences between obese-IS and obese-IR 
subjects were evaluated using the Student’s t test for continuous variables and 
Fisher’s exact test for categorical variables.  In a secondary analysis, baseline 
differences between all obese (combined obese-IR and obese-IS) and non-
obese-IS subjects were evaluated using the same methods. Variables with a 
skewed distribution (total cholesterol, LDL cholesterol, HDL cholesterol, 
triglycerides, fasting glucose, fasting insulin, HOMA, AST, ALT, CRP, total 
monocyte count, leptin) were log-transformed before analysis.   
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Tables 
 
 Table 6.1. Selected measures obtained at the study visit  
Measure Description
Demographcs Age, sex, race, 
Clinical data Chronic medical conditions, current medications, family history of T2DM
Physical examination Height, weight, blood pressure, waist circumference, pubertal staging
Fasting blood draw Glucose, insulin, lipid panel, liver enzymes, complete blood count with differential, 
inflammatory markers, monocytes
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CHAPTER VII 
 
7. Experimental Evaluation (Part 2) 
 
7.1 Study sample characteristics 
  
Blood samples from eleven female subjects were used in this study.  This pilot 
study was limited to females to minimize variability associated with gender.  
Using HOMA-IR analysis, we divided the subjects into three groups: obese-IR 
(n=4), obese-IS (n=3) and 4 nonobese-IS (n=4) (for definitions of IR and IS see 
6.1 Adolescent Subject Recruitment”).  The obese subjects were younger and 
displayed a larger waist circumference, higher systolic blood pressure, higher 
fasting insulin and more systemic leptin as compared to the nonobese-IS 
subjects (Table 7.1).  The obese-IR subjects had, on average, a BMI that was 
higher than the obese-IS subjects, but this difference did not reach statistical 
significance (Table 7.1).  Obese-IR subjects showed significantly elevated 
glucose, insulin and HOMA-IR as compared to obese-IS subjects (Table 7.1).    
All subjects provided written informed consent before taking part in the study. 
 
7.2 Monocyte purity 
Data were collected from the monocyte fraction and non-monocyte fraction of 
blood acquired from a healthy research volunteer.  The purity of the enriched 
monocytes obtained using the MiltenyiTM Monocyte Isolation Kit II was 
determined by flow cytometry.  This kit uses an indirect magnetic labeling system 
to isolate all cells types except monocytes.  Aliquots of the cell fractions were 
stained with fluorochrome-conjugated antibodies against a monocyte marker 
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(CD14-FITC), a B-cell marker (CD19-APC), and a T-cell marker (CD8-PE).  The 
monocyte fraction contained 85% CD14+ cells (Figure 7.1), compared with the 
non-monocyte fraction which contained <1% CD14+ cells (Figure 7.2).   
 
7.3 Monocyte proinflammatory phenotype 
 
Expression of two cytokine signaling molecules (IL8, suppressor of cytokine 
signaling 3 (SOCS3)) and two downstream products of the JNK pathways (JunB, 
c-Fos) were measured from the CD14+ monocytes in our 3 subject groups.  Both 
IL8 and SOCS3 showed a trend towards increased expression in the obese-IR 
subjects compared to the obese-IS and nonobese-IS subjects (Figure 7.3), 
suggesting the presence of a proinflammatory phenotype in monocytes in 
obesity, which is exacerbated in the insulin resistant state.   Expression of JunB 
and c-Fos, two members of the Jun and Fos family of AP-1 transcription factors, 
trended higher in obese-IR patients than obese-IS and nonobese-IS subjects 
(Figure 7.4), indicating enhanced activation of the JNK pathway.  In addition, the 
circulating levels of IL8, IL6 and TNFα were higher in obese-IR subjects 
compared to obese-IS subjects and nonobese-IS subjects (Figure 7.5).     
 
7.4 Conclusions 
 
The results from this pilot study in lean, obese-IS and obese-IR young females 
suggest that circulating monocytes are in a proinflammatory state in obesity, and 
this inflammation is exacerbated in the insulin resistant state.  Our insulin 
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resistant cohort displayed an increased waist circumference, suggesting a larger 
visceral fat depot than the insulin sensitive patients.  In addition, the elevated 
leptin level is not surprising as these patients likely have more fat mass than their 
peers in this study.  The increased systemic levels of IL6 in the obese-IR cohort 
is consistent with cross-sectional data indicating a strong association between IR 
and IL6 levels8
 
. 
The increased systemic level of IL8 as well as the increased expression of IL8 in 
monocytes of subjects in the obese-IR cohort suggest a potential role for IL8 in 
the pathophysiology of insulin resistance and a possible source of IL8 production.  
IL8, a member of the CXC chemokine family, is known to be stimulated by TNFα 
and secreted by adipocytes, particularly those in the visceral depot55.  We have 
shown that in our sample of obese-IR young girls, elevated levels of TNFα may 
increase IL8 production and stimulation from circulating monocytes resulting in 
an increase in systemic IL8 levels which is consistent with other reports56.  IL8 is 
thought to induce insulin resistance via the inhibition of insulin-induced Akt 
phosphorylation, providing a link between obesity and obesity-related 
comorbidities55
 
. 
SOCS-3 inhibits the signal transduction of several cytokines, including leptin, via 
its disruption in the Janus-activating kinase2-signal transducer and activator of 
transcription 3 (JAK2-STAT3) pathway on leptin receptors57.  Leptin resistance is 
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a common feature of obesity, and results in decreased fatty acid oxidation, 
excessive fat storage, and impaired satiety58.  In addition to its role in leptin 
resistance, SOCS3 also inhibits insulin signaling by binding to phosphorylated 
Tyr960 of the insulin receptor59, suggesting another potential role in the 
development of insulin resistance.   Hepatic SOCS3 is known to be a mediator of 
insulin resistance in the liver47,60 and our data suggest that SOCS3 may also play 
a role in altering monocyte insulin signaling.  In addition, prior work in patients 
with chronic kidney disease reveals increased expression of SOCS3 in 
monocytes that is associated with increased plasma levels of IL6 and TNFα, and 
with progressive loss of renal function61
 
.  In this study, the authors speculate 
whether SOCS expression could be a marker of subacute cardiovascular 
disease, and a possible target for therapeutic intervention.   
The JNK signaling pathway is known to be strongly associated with the 
development of obesity-associated inflammation62.  JunB and c-Fos, two proteins 
with increased expression in our obese-insulin resistant cohort, can dimerize and 
form the AP-1 transcription factor and activate target genes, most notably those 
associated with inflammation62.  This pathway is activated in adipose tissue and 
the liver in the obese state, and our data suggest that it is also activated in 
inflammatory cells, namely monocytes.  This is consistent with prior work 
showing that inhibition of JNK in macrophages results in reversal of diet induced 
insulin resistance, without affecting obesity44. 
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Our data are consistent with recent evidence suggesting that immune cells may 
be a key pathway whereby obesity and circulating free fatty acids contribute to 
systemic inflammation and insulin resistance.  We showed that in female 
teenagers and young adults, obesity can induce a proinflammatory phenotype in 
circulating monocytes characterized by increased expression of proinflammatory 
cytokines, and proteins that are known to impair insulin sensitivity (Figure 7.6).  
In addition, these activated monocytes can be recruited to populate the adipose 
tissue as macrophages.  Novel therapeutic interventions that decrease monocyte 
activation may delay or prevent obesity-related co-morbidities. 
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Obese Insulin 
Resistant
Obese Insulin 
Sensitive
Non-obese 
Insulin 
Sensitive
P Value 
Obese-IR vs. Obese-IS
P Value 
(Obese-IR + Obese-IS) 
vs. Non-obese-IS
  HOMA < 3.16 HOMA < 3.16
(N= 4) (N= 3) (N= 4)   
16.5 ± 0.5 17.7 ± 1.7 22.4 ± 3.3 0.22 <0.01
White race 25% 67% 50% 0.48 1
42 ± 11  35 ± 6 22 ± 3 0.33 0.01
Waist circumference, cm 121 ± 24 103 ± 8 80 ± 8 0.26 0.01
130 ± 15 113 ± 4 104 ± 3 0.14 0.03
Diastolic blood pressure, mm Hg 73 ± 9 69 ± 15 66 ± 8 0.66 0.43
Medical History
Polycystic ovarian syndrome 50% 33% 0% 1 0.24
First-degree relative with T2DM 75% 66% 25% 1 0.24
88 ± 8 70 ± 4 73 ± 8 0.01 0.32
21 ± 7 5 ± 6 2 ± 1 0.02 0.04
4.6 ± 2 0.9 ± 1 0.45 ± 0.2 0.02 0.04
Total cholesterol, mg/dL 129 ± 33 121 ± 22 132 ± 42 0.81 0.79
LDL cholesterol, mg/dL 77 ± 19 64 ± 10 73 ± 35 0.4 0.9
HDL cholesterol, mg/dL 36 ± 8 44 ± 17 48 ± 7 0.61 0.21
Triglycerides, mg/dL 77 ± 42 69 ± 32 59 ± 17 0.93 0.7
AST, IU/L 18 ± 5 15 ± 3 16 ± 3 0.29 0.72
ALT, IU/L 24 ± 11 17 ± 7 14 ± 4 0.34 0.19
CRP, mg/L 5.3 ± 5 6.2 ± 8 <1 ± 0 0.88 0.17
Total monocyte count/mm3 658 ± 165 456 ± 105 375 ± 99 0.12 0.08
Leptin, pg/mL 4343 ± 3068 3409 ± 1850 1036 ± 702 0.89 0.01
§ The body-mass-index (BMI) is the weight in kilograms divided by the square of the height in meters.
Fasting glucose, mg/dL
Fasting insulin,  mIU/mL
HOMA-IR
* Plus-minus values are mean (± SD).
Table 7.1. Clinical and Biochemical Characteristics of Study Participants*
Age, years
Systolic blood pressure, mm Hg
BMI§
 
HOMA ≥ 3.16 
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Figure Legend 
 
Figure 7.1. Confirmation of monocyte purity. Flow cytometry showing the relative 
distribution profiles of CD14- (negative) and CD14+ (positive with anti-CD14 
antibody conjugated to FITC) cells in the purified monocyte fraction.  Data 
obtained from sample gated on forward and side scatter parameters that are 
appropriate for a monocyte population.  
 
Figure 7.2. Confirmation of monocyte purity. Flow cytometry showing the relative 
distribution profiles of CD14- (negative) and CD14+ (positive with anti-CD14 
antibody conjugated to FITC) cells in the purified monocyte-depleted (non-
monocyte) fraction. Data obtained from sample gated on forward and side scatter 
parameters that are appropriate for a monocyte population.  
 
Figure 7.3. Expression of inflammation-related genes in the NFκB pathway in 
monocytes from non-obese (n=4), obese-IS (n=3) and obese-IR (n=4) subjects 
using qRT-PCR. Fold change in mRNA level of cytokines. Data were normalized 
to beta2-microglobulin.  Error bars represent SEM. 
 
Figure 7.4. Expression of inflammation-related genes in the JNK pathway in 
monocytes from non-obese (n=4), obese-IS (n=3) and obese-IR (n=4) subjects 
using qRT-PCR. Fold change in mRNA level of transcription factors. Data were 
normalized to beta2-microglobulin.  Error bars represent SEM. 
 
Figure 7.5.  Serum levels of cytokines and chemokines in obese-IR, obese-IS 
and nonobese-IS subjects.  Each data point represents an individual subject, the 
line represents the mean for that subject group.  Data was unavailable for one 
patient in the obese-IS group due to technical difficulties. 
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Figure Legend 
 
Figure 7.6. Potential mechanisms linking obesity to immune cells and insulin 
resistance.  (A) Caloric excess leads to adipocyte hypertrophy resulting in 
increased secretion of the monocyte chemoattractant CCL2.  Monocytes are 
recruited to adipose tissue, differentiate into macrophages, and secrete 
chemokines that recruit additional monocytes, as well as cytokines that can 
activate monocytes, and impair insulin signaling.  (B) Inflammatory pathways in 
circulating monocytes are activated by free fatty acids, TNFα or IL1β.  Once 
activated, these monocytes can secrete cytokines that promote activation of 
other monocytes, or directly impair insulin signaling. 
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CHAPTER VIII 
 
8. Final Summary and Future Work 
This body of work implicates inflammatory cells, specifically macrophages and 
circulating monocytes, as key players in the pathophysiology of insulin 
resistance.  The next step is to conduct a larger study to confirm the findings of 
monocyte inflammation observed in this pilot study in an adolescent population.   
  
I am proposing to carry out a case-control study in young obese adolescent 
males and females between the ages of 12 and 18 years that will test the 
hypotheses that peripheral blood monocytes from obese-IR individuals (cases) 
when compared to obese-IS individuals (controls) demonstrate enhanced 
activation of inflammatory signaling pathways and proinflammatory cytokine 
secretion.  The knowledge gained from this study will advance our understanding 
of the contribution of monocytes to the pathophysiology of IR in obesity, and may 
provide a readily measurable serum biomarker that can be used to identify high 
risk patients, track the progression of disease, and monitor responses to 
behavioral or pharmacologic therapies.  
 
Specific Aim 1. Identification of a monocyte pro-inflammatory profile in obesity-
induced IR.  This aim will test the hypothesis that circulating monocytes from 
obese-IR individuals are more likely to exhibit a proinflammatory subtype as 
compared to monocytes from obese-IS individuals.  We will use immuno-
magnetic bead separation to isolate a population of pure monocytes from obese-
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IR and obese-IS subjects.  The distribution of pro-inflammatory CD14+CD16+ and 
classical CD14+CD16-
 
 monocytes will be determined using flow cytometry to 
quantify the signature cell surface markers and chemokine receptors that 
distinguish these two monocyte subsets.  These studies will characterize the 
distribution of two monocyte subtypes in the IR state. 
Specific Aim 2. Critical evaluation of the capacity of monocytes from obese-IR 
individuals to secrete proinflammatory cytokines characteristic of obesity-induced 
IR.  This aim will test the hypothesis that circulating monocytes from obese IR 
subjects have a stable potential for increased secretion and expression of pro-
inflammatory cytokines as compared to monocytes from obese-IS individuals.  
Serum biomarkers of inflammation (TNFα, IL1β, IL6, IL8, MCP-1, IL10) will be 
measured in obese-IR and obese-IS youth.  Spontaneous and stimulated 
secretion from cultured monocytes isolated from obese-IR subjects will be 
critically evaluated and compared to corresponding data from obese-IS subjects.  
Gene expression of key inflammatory cytokines will be measured in monocytes 
using quantitative PCR.  These studies will establish a potential role for 
monocytes in the development of systemic inflammation seen in obese-IR. 
  
Specific Aim 3. Identification of inflammatory signaling pathways that are 
activated in monocytes in obesity-induced IR.  This aim will test the hypothesis 
that IKKβ-NFκB and JNK-AP1 signaling pathways are activated in monocytes 
from obese-IR patients as compared to monocytes from obese-IS individuals.  
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Immunohistochemistry will be used to assess localization of key transcription 
factors.  In addition, phosphorylation states of specific proteins in these two 
pathways will be analyzed.  These studies will provide insights into the molecular 
alterations present in monocytes from obese-IR individuals, and may identify 
potential therapeutic targets to ameliorate the inflammatory state.  
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